Tozinameran
Tozinameran (BNT162b2, Comirnaty) is an mRNA vaccine encoding the SARS-CoV-2 spike protein, encapsulated in lipid nanoparticles that facilitate cellular uptake and endosomal escape, allowing ribosomes to translate the spike protein and trigger humoral and cellular immune responses. It was the first mRNA vaccine authorized for widespread human use, providing highly effective protection against COVID-19 and being extensively used in global vaccination campaigns. The mRNA-lipid nanoparticle platform it established is now being investigated for vaccines against HIV, cancer, and other diseases.
Áreas terapéuticas
Mecanismo de acción
Delivers synthetic messenger RNA encoding a specific protein to host cells, where it is translated by ribosomes to produce the therapeutic protein without integrating into the host genome.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Delivers synthetic messenger RNA encoding a specific protein to host cells, where it is translated by ribosomes to produce the therapeutic protein without integrating into the host genome.
HBD / HBA
- / -
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
Tozinameran (BNT162b2, Comirnaty) is an mRNA vaccine encoding the SARS-CoV-2 spike protein, encapsulated in lipid nanoparticles that facilitate cellular uptake and endosomal escape, allowing ribosomes to translate the spike protein and trigger humoral and cellular immune responses. It was the first mRNA vaccine authorized for widespread human use, providing highly effective protection against COVID-19 and being extensively used in global vaccination campaigns. The mRNA-lipid nanoparticle platform it established is now being investigated for vaccines against HIV, cancer, and other diseases.
Delivers synthetic messenger RNA encoding a specific protein to host cells, where it is translated by ribosomes to produce the therapeutic protein without integrating into the host genome.
Yes, Tozinameran is an approved drug. It has reached clinical phase 4. It is classified as a Vaccine component.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4650429. Open-access bioactivity database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="tozinameran"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/tozinameran/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/tozinameran/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/tozinameran/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="tozinameran"></drugfyi-drug>